» Articles » PMID: 16865818

Prediction of in Vivo Drug Clearance from in Vitro Data. II: Potential Inter-ethnic Differences

Overview
Journal Xenobiotica
Publisher Informa Healthcare
Specialties Biochemistry
Toxicology
Date 2006 Jul 27
PMID 16865818
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Potential differences in drug clearance between Japanese and Caucasians were investigated by integrating data on demography, liver size, the abundance of the major cytochromes P450 and in vitro metabolic parameters. Eleven drugs (alprazolam, caffeine, chlorzoxazone, cyclosporine, midazolam, omeprazole, sildenafil, tolbutamide, triazolam, S-warfarin and zolpidem) fulfilled the entry criteria of the study (i.e. the necessary in vitro metabolism data were available and clearance values had been reported both in Caucasians and Japanese). Values of relevant biological variables were obtained from the literature, and clearance predictions were made using the Simcyp Population-Based ADME Simulator. The ratios of observed oral clearance (CLp.o.) values in Caucasians compared with Japanese ranged from 0.6 to 2.8 (integrating data from 82 sources). The CLp.o. values for alprazolam, caffeine and zolpidem were not statistically different between Caucasian and Japanese (p>0.05), whereas those for chorzoxazone, cyclosporine, omeprazole, tolbutamide and triazolam were higher in Caucasians (p<0.05), and those for midazolam, sildenafil and S-warfarin were higher in Japanese (p<0.05). CLp.o. values, predicted from in vitro data, were within 3-fold of observed in vivo values for seven of the 11 drugs in Japanese. Values for the predicted ratios ranged from 1.6 to 4.9. The predicted ratios were not significantly different from observed ratios for cyclosporine, omeprazole, tolbutamide and triazolam. Only partial success in predicting ethnic differences in clearance indicates the need for larger and more reliable databases on relevant variables. With such information, in silico predictions might be used with more confidence to decrease the need for repeating pharmacokinetic studies in different ethnic groups.

Citing Articles

Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children.

Traver E, Rodriguez-Pascau L, Meya U, Pina G, Pascual S, Poli S CPT Pharmacometrics Syst Pharmacol. 2024; 13(6):982-993.

PMID: 38549500 PMC: 11179696. DOI: 10.1002/psp4.13132.


PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Metabolism in Pregnant Subjects and Fetuses.

Le Merdy M, Szeto K, Perrier J, Bolger M, Lukacova V Pharmaceutics. 2024; 16(1).

PMID: 38258106 PMC: 10820132. DOI: 10.3390/pharmaceutics16010096.


Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model.

Iijima H, Shimizu H, Mori-Anai K, Kawaguchi A, Mochida Y, Yamauchi T Diabetes Ther. 2023; 15(4):763-777.

PMID: 38117459 PMC: 10951162. DOI: 10.1007/s13300-023-01514-1.


A Systematic Review on Antimicrobial Pharmacokinetic Differences between Asian and Non-Asian Adult Populations.

Setiawan E, Cotta M, Roberts J, Abdul-Aziz M Antibiotics (Basel). 2023; 12(5).

PMID: 37237706 PMC: 10215324. DOI: 10.3390/antibiotics12050803.


Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases.

Ahmed M, Burnham J, Dwivedi G, Abuasal B J Pharmacokinet Pharmacodyn. 2023; 50(6):429-444.

PMID: 37140724 DOI: 10.1007/s10928-023-09863-x.